SLC5A2 and type 2 diabetes mellitus: A study by Kim et al. demonstrated that therapy with the SGLT2 inhibitor empagliflozin in individuals with T2D and a high CV risk attenuated NLRP3 inflammasome activation and the secretion of IL-1β [103].